June 7 Company Quick Takes: Expanded label for PTC’s DMD drug; plus Achaogen, ICER on migraine and Nucala

PTC’s DMD drug approved in patients ages 2-5
FDA approved an sNDA for Emflaza deflazacort from PTC Therapeutics Inc. (NASDAQ:PTCT) to treat Duchenne muscular dystrophy in patients ages 2-5. The drug was first approved in 2017 to treat DMD patients five years and older.

Achaogen gets $16M in bankruptcy sell-off
Antibiotic company Achaogen Inc. (NASDAQ:AKAO) sold off substantially all of its assets for $16 million in an auction after filing for bankruptcy in April, plus royalties and assumption of certain liabilities. The U.S. subsidiary of Cipla Ltd. (NSE:CIPLA; BSE:CIPLA) bought ex-China worldwide rights to Zemdri plazomicin, and Qilu Pharmaceutical Co. Ltd. (Jinan, China) purchased royalty-free rights in Greater China. FDA approved Zemdri to treat complicated urinary tract infections last year (see “Achaogen Files for Bankruptcy Amid Continued Headwinds for Antibiotic Developers”)...